MK-5108 (VX-689) is primarily investigated for its potential in cancer treatment. It functions as an Aurora A kinase inhibitor, targeting and inhibiting the activity of this enzyme, which plays a critical role in cell division and proliferation. By blocking Aurora A kinase, MK-5108 disrupts the mitotic process in cancer cells, leading to cell cycle arrest and apoptosis. This makes it a promising candidate for therapeutic applications in various cancers, particularly those characterized by uncontrolled cell growth. Research is ongoing to evaluate its efficacy in preclinical and clinical settings, often in combination with other anticancer agents to enhance treatment outcomes. Its application is focused on improving therapeutic strategies for malignancies with high unmet medical needs.